Degree BSc, MB ChB, FRCPC
Office: Parkwood Institute
Michael Borrie, MB ChB, FRCPC is a Geriatrician and Professor at Western University, Schulich School of Medicine and Dentistry, Department of Medicine, Division of Geriatric Medicine. He was an MRC (New Zealand) Training Research Fellow 1983-1985 in Dunedin, New Zealand. He completed his training in Internal Medicine in Edmonton, Alberta and London, Ontario and in Geriatric Medicine in London, Ontario.
He is presently the Medical Director for the Aging Brain and Memory Clinic, an investigator with the Cognitive Clinical Trials Group, Program Director of the South Western Ontario Regional Geriatric Program and Past Chair of the Division of Geriatric Medicine, Department of Medicine, Western. His research interests include predictors of conversion from mild cognitive impairment (MCI) to Alzheimer Disease (AD), including sensitive Neuroimaging techniques, and randomized controlled trials of new treatments for MCI and AD. He is the President of the Consortium for Canadian Centres for Clinical Cognitive Research (C5R).
The Cognitive Clinical Trials Group Team consists of investigators, clinical trials coordinators, clinicians and research assistants who do research in Mild Cognitive Impairment and Alzheimer Disease. The team is based at Parkwood Institute (formerly Parkwood Hospital) and conducts investigator initiated and pharmaceutical sponsored randomized controlled trials. As well, they provide education and clinical support to people with cognitive impairment and their families who are in the community. The Cognitive Clinical Trials Group collaborates with Dr. Rob Bartha, Neuroimaging Scientist at the Robarts Research Institute, and his team of graduate students. These investigator initiated neuroimaging studies have examined early markers of disease progression from Mild Cognitive Impairment to Alzheimer Disease using magnetic resonance spectroscopy (MRS) and structural MRI at high magnetic field intensity. Our collaboration has led to the development of MRI software that precisely measures changes in brain ventricular quantification (BVQ) of the lateral ventricles over 6 month intervals. This software has been tested on the Alzheimer Disease Neuroimaging Initiative (ADNI) MRI database. The Clinical Trials Group is one of the sites for the ADNI, ADNI-GO and ADNI-2 studies. Our goal is to study new compounds in people with Alzheimer Disease using neuroimaging biomarkers that could signal support for further development of the studied compounds.
University Held Positions
Professor, Department of Medicine, Division of Geriatric Medicine, University of Western Ontario.
Past Chair, Division of Geriatric Medicine, University of Western Ontario.
Head, Department of Geriatric Medicine, Parkwood Hospital.
Medical Director, Aging Brain and Memory Clinic, Parkwood Hospital.
Medical Director, Dementia Special Care Unit, Western Counties Wing, Parkwood Hospital.
Program Director, Southwestern Ontario Regional Geriatric Program.
Chair, Protocol Review and Selection Committee, Consortium of Canadian Centres for Clinical Cognitive Research (C5R)
Director, Geriatric Clinical Trials Group, UWO/Lawson Research Institute, Parkwood Hospital.
Areas of Clinical Interest
Mild cognitive impairment
Areas of Research Interest
Research interests include predictors of conversion from mild cognitive impairment (MCI) to Alzheimer Disease (AD), including sensitive Neuroimaging techniques, and the clinical evaluation of new treatments for AD, geriatric rehabilitation and falls in the elderly.